ARVO

ARVO

Source:

Ousler G, et al. Safety and efficacy of ophthalmic mitochondrial reactive oxygen species scavenger Visomitin for the treatment of dry eye disease: findings of VISTA-1 and VISTA-2 studies. Presented at: Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver.

Disclosures: Ousler is employed by Ora Inc.
May 19, 2022
1 min watch
Save

VIDEO: SkQ1 reduced corneal staining, improved vision in dry eye

Source:

Ousler G, et al. Safety and efficacy of ophthalmic mitochondrial reactive oxygen species scavenger Visomitin for the treatment of dry eye disease: findings of VISTA-1 and VISTA-2 studies. Presented at: Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver.

Disclosures: Ousler is employed by Ora Inc.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

DENVER – Treatment with the mitochondrial reactive oxygen species scavenger Visomitin resulted in reduced corneal staining and improved visual function in patients with dry eye, according to a study presented here at ARVO.

George Ousler, Ora Inc. senior vice president of anterior segment, said that Mitotech’s SkQ1 ophthalmic solution is a “novel therapeutic approach to dry eye.”